• The partnership will see the adoption of Mesh Bio’s predictive analytics software to advance diagnostic services across more than 30 centres in Indonesia by PT Pramita.  
• Mesh Bio’s proprietary software will be able to deliver personalised preventive care and disease risk by providing actionable health insights for each patient. 

The Memorandum of Understanding (MOU) was signed by Dr Andrew Wu, Co-Founder and CEO of Mesh Bio and Dr Nabil Fachliansyah, Vice President of PT Pramita. It was witnessed by Singapore Minister for Trade & Industry Gan Kim Yong and Indonesian Coordinating Minister for Economic Affairs Airlangga Hartarto as part of the Singapore-Indonesia Leaders’ Retreat held in Singapore. 
 
According to a recent study on the state of health in Indonesia published by The Lancet, chronic diseases continue to affect the health of many Indonesians – amongst the top five leading risks contributing to health loss measured in disability adjusted life years (DALYs) in 2019 were high systolic blood pressure, high fasting plasma glucose, high BMI and more. These risk factors commonly lead to chronic conditions such as diabetes, obesity and hypertension. The impetus to manage the burden of non-communicable diseases has thus been identified by the government to be urgent health policy concerns, especially so due to the high cost involved to treat and manage such diseases in a population that has increased its life expectancy by 6-8 years on average since 1990. The partnership between Mesh Bio and Pramita aims to address this through the use of Mesh Bio’s proprietary software – DARA® Health Intelligence Platform.  
 
Powered by an analytics engine that combines metabolic disease digital twins, data science and predictive analytics, the leading digital health platform in Singapore, enables healthcare providers to deliver personalised preventive care with intelligent healthcare data. DARA® improves patient engagement and health outcomes by providing actionable health insights through personalised disease risk and adverse event predictions. This first-in-class solution will be rolled out in Indonesia for the first time and enable precision patient intervention to be delivered to a large population in an affordable and scalable manner.  
 
“With a growing ageing population across the globe, delivering innovative solutions to address the healthcare burden of chronic diseases has always been at the core of Mesh Bio. We are thrilled to be able to take our solutions to new shores with Pramita. With more than 30 centres all over Indonesia, we believe the partnership will improve the patient experience and drive more positive health outcomes for Indonesians as we tackle the growing chronic disease burden.” said Dr Andrew Wu, Co-Founder and CEO of Mesh Bio. 
 
“Mesh Bio has extensive knowledge and innovations in the healthcare space that can enhance how we deliver preventive care services to our customers. The MOU underscores the shared commitment we have to advance healthcare offerings for Indonesians. We look forward to catalysing greater collaboration in the adoption of digital solutions within the healthcare industry, including exploring the possibilities of deep-tech solutions across other fields of medicine and healthcare services.” said Dr Nabil Fachliansyah, Vice President of PT Pramita.